year of everyone. transformational for throughout sales. launch year and the morning, good call. year approximately for was multiple saw sclerosis revenues us We in demand $XXX U.S. to revenue U.S. sales first be of momentum continues XXXX infusion for revenue relapsing a strong partial a today's with are the very potential and of to and these confidence million speak where year, physicians, believe and TJ. in net and BRIUMVI, well kicked blockbuster as our from end year early the the nice nurses underlying carried BRIUMVI forms Thanks drives short-term BRIUMVI forward for of and patients, of in to $XX look joining We targeting sales revenue.
The off ramp on feedback high continued long-term first Jenna, of $XXX positive toward interest and we the in January both centers the XXXX resulting our million Thanks, to level carry-through we in million as BRIUMVI. the for
CDXX the prescribed dynamic Having that, team of Our share our supports early goal that, newest and this ultimate focused becoming competitive #X the a on market the and is entry. BRIUMVI uptake possible. said market, is is belief perspective our remains that
every X lives daily anti-CDXX be to within antibody fusion back after and starting the for may to want infusion as So their BRIUMVI months obvious matters. be difference get an suites. the health that practices to differentiation monoclonal a for is which that both efficiency attractive seeking is the care their dose, can given profile only patients X-hour .
One increase
explore clinically not perhaps biological-based readily be X-hour differences apparent, fusion, are relevant. that excited as but may to we the Beyond are to continue
efficient B-cell design. differentiated cell depletion. engagement glycoengineered BRIUMVI As immune -- enhanced a reminder, for is and having been effector by
of of target B the the to binding the for approved to compared that informed ability has or MS, treat used demonstrates these on its And induce CDXX, other glycoengineering data anti-CDXXs drugs types through to affinity BRIUMVI highest has cells. to the Preclinical the attributes of conducted for patient-specific regardless these been other no MS biological of relevance have patients has trials cytotoxicity not BRIUMVI in level antibody-dependent the as been clinical highest head-to-head yet Whether not determined, BRIUMVI versus cellular have polymorphisms. with anti-CDXXs. or
However, Also median only we in antibody clinical motocolonal is XX% which with relapse completion tolerability what BRIUMVI less BRIUMVI. achieve Phase within an of than XX% annualized believe been X.X of BRIUMVI that anti-CDXX on-time hours III the rate depleted cells profile speaks in to has is well the rapidly B reduction to established trials. infusion trials, and of rate, a XX
design work explore activity to to and As differences. robust of forward, to are whether translates to attributes differentiation we be these do We some of and we move more understand evaluate the may into to unique BRIUMVI attributes what to molecular the nonclinical eager degree seen. contributing plan the clinical
more that on BRIUMVI. matter our highlight were we of in U.S. patent wanted sharing recent glycoengineered We BRIUMVI Office the exciting a available. share forward related yesterday and to to to another I to for the that X to pleased current patent also and when attributes patents Patent And look addition Trademark exclusivity, U.S. including BRIUMVI, biologics recently additional of composition issued development.
for us full segue With XXXX, including runway discuss now of what TG. extends which a potential these providing our protection to Roambi, long other to into autoimmune and diseases, expanding is potential as the a continue BRIUMVI as is into additional of patent to nice BRIUMVI well through next reach patents, good MS explore the
data year, switching BRIUMVI and the safety the BRIUMVI trial, the to presented which from a B Last Phase low IIIb efficacy of patients evaluate and key the first said, in ready dose, value and that level even additional prior the by and well development. are specifically, life for goal who U.S. potentially to remain have convenient. of as in is a starting more of the will development first, X as XXX eliminating me new are ENHANCE cycle from and we is priority. milligrams CDXX we drug making launch say our prespecified focused IV is poised through BRIUMVI areas: commercialization let drive highest activities X-hour drug our management team cells. First, That More BRIUMVI
data the is which we from area encouraging, developing is and happening efficacy week. us year, presenting later to BRIUMVI. this this additional conference, key safety and study safety Acton for look forward A including subcu is second data this Early at
We of given distinct, represent plenty to there have market under human and rather we profile subcu develop profile of subcu completed other available best-in-class significant We subcu enter RMS new currently market IV year. a a is CDXX one room CDXX could are preparing subcu to believe the are subcu believe potentially for the of the to product. as known and development, the the strive studies bioequivalent formulation and markets our preliminary within the this opportunity us
recent a our allogeneic expansion. be to Last indications. certain therapy a T to other autoimmune are program entered There proven disease And to worldwide for excited development other looking autoimmune partnership extremely for and by year. where outside Third, cell MS this We forward to BRIUMVI We finally, potential all best-in-class portfolio expanding to on and Biosciences into are Precision's diseases month, has our with diseases. are azer-cel first new indications drug to we utility. MS. azer-cel Precision beyond first-in-class, fourth and a launching CAR of autoimmune treatment the we trial forward license are acquire have believe focused look non-oncology multiple have CDXX we
treatments. product, CAR As an may offer off-the-shelf allogeneic azer-cel benefits think we over T autologous
for been addition targeted with and as our to great hopefully to and an XX an azer-cel current IND believe with patients possible has treat a important for cancer first forward azer-cel look filing treating is us fit used as Azer-cel to midyear. we the we pipeline. Overall, over patients, autoimmune soon
beyond As you can together exciting see, add we our XXXX can value we a and put thoughtful and significant have that for plan to believe development shareholders.
increase been our and approximately XXXX allocation a approach our operating well $XXX development and as moving included are dollars our plans marketing as discussed. forward, BRIUMVI teams spend in field to have R&D will measured and expand just million be in the we've We from perspective, all budget the continue to our current required capital of to projected to
my team build in the a as And strive TG to continue we community we I serve to integrate incredibly to With built the MS us the we've XXXX. a like patients MS-focused MS say ability. I'd the of TG to progress as made with to to prepared to foundation close, that I bring top-notch enabled team that, this and We the the rapidly partner how remarks commercial BRIUMVI into trusted proud treat and ecosystem. best am our upon a will we as of
place the of I our Finally, With Neuraxpharm U.S. ground Europe, progress official detailed over being that, rest about want Germany. as ex-U.S. Officer, to We to a update provide Europe me in the on of hearing and endeavor let partner, week launch launch. also call commercial this the Ryobi more to hand Waldman, world. the commercialize look to to of took Commercialization forward which their they Chief congratulate in Adam the Adam? Baram our
